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1. Introduction 
Neural stem cells are present in both the developing and adult nervous system of all 
mammals, including humans. Due to their therapeutic promise, considerable attention has 
been focused on identifying the sources of stem cells, the signals that regulate their 
proliferation and the specification of neural stem cells towards more differentiated cell 
lineages (Bauer et al., 2006). Presently, neural stem cells are often identified based upon the 
presence of molecular markers that are correlated with the stem and/or progenitor state 
along with the absence of a more differentiated phenotype as assessed through marker 
analysis. Nevertheless, from the very beginning of NSC research the frame was set by the 
search for such markers and some have been identified, which, at least, allow for the 
identification of NSC clonal cells in cell culture. Still, the task proves to be difficult because 
of the changing identity that NSC can undergo and the demands that are imposed on 
markers. A reliable marker should identify NSC not only in the embryonic brain but also in 
the adult brain. Generally, markers may either be selected for cell function or for some 
phenotypic differences. There exist several commonly used immunomarkers for the 
identification of cells of neural lineages. CD 15 (SSEA1), CD133 (Prominin-1), CD184 
(CXCR4) , CD271 (p75-NTR), CDw338 (ABCG2), Ki67, Musashi-1, Musashi-2, nestin, Notch-
1, PAX-6, SOX-1, SOX-2 are known as neural stem cell markers; PSA-NCAM and 
CD271(p75-NTR) as neuronal restricted progenitor markers; CD56 (N-CAM), MAP2, DCX, 
ǃ-III- A2B5 and NG2. GFAP, FGFR3, Ran-2, S100B and CD44 (H-CAM) are known as Type 1 
astrocyte, and GFAP, A2B5, CD44 and S100B as Type 2 astrocyte markers. The tubulin and 
neurofilament NF-H are used as neuron markers. Glial restricted progenitor markers are 
differentiation of glial restricted progenitors to oligodendrocyte progenitors has been 
marked by A2B5, NG2, Olig2 and CD140a (PDGFRǂ). GalC, MBP, CD140a (PDGFRǂ), O1, 
O4, Olig1, Olig2 and Olig3 have been used as mature oligodendrocyte markers. In addition 
CD57, CD271 (p75-NTR), MASH1, Neurogenin 3 and Notch-1 have been used as neural 
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crest stem cell markers (Kennea & Mehmet, 2002; Schwartz et al., 2008; Yuan et al., 2011). 
The expression overlap of markers requires a use of different immunomarkers for the 
identification of specific cells in neural lineages. The most problematic point, however, is the 
potential pitfall in identifying the phenotype of any newborn cell by a single marker. There 
exists a great need for more and specific monoclonal antibodies as immunomarkers for the 
characterization of both normal and malignant neural cells. 
2. Aim of the study 
The main aim of the study is the development of new monoclonal antibodies (MAbs) against 
neuronal tissue cells to investigate the differentiation and malignization of human nerve cells. 
The antibody producing hybridomas were obtained by immunizing Balb/c mice with the 
native fragments of human glioblastoma and foetal neural stem/progenitor cells (see Fig. 1). 
 
Fig. 1. Flow chart of developing hybridomas and monoclonal antibodies. 
In this way it is possible to obtain MAbs against all kinds of antigenic determinants 
(proteins, glycans and lipids and conformational complex epitopes) that are co-expressed in 
the living cell, also including those determinants that are expressed on the cell surface. Used 
immunization scheme allows to obtain MAb panels which characterise the given cell type, 
including tumour cells. It is possible to obtain MAbs, differentiating between normal and 
tumour cells. Such specific antibodies against cell surface antigens may be the primary 
candidates for therapeutic antibodies and/or diagnostic purposes. 
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3. Methods 
3.1 The isolation of human fetal neural stem/progenitor and glioblastoma spheroid 
cells 
Human fetal neural stem/progenitor and glioblastoma spheroid cell lines were developed as 
described earlier (Kalev et al., 2006). In a greater detail, stem cells were isolated from the brains 
of 18-21-weeks old fetuses aborted due to medical indications (pregnancy problems). The 
study was approved by the Ethics Review Committe on Human Research of the University of 
Tartu. The tissue was mechanically dispersed into a cell suspension in the DMEM/F12 
medium, containing gentamicin as antibiotic (Gibco BRL, Gaithersburg, USA). The cell 
suspension was centrifuged and washed once with the same medium and seeded into 6-well 
tissue culture plates with a density of 5000-10000 living cells per ml in the medium composed 
of DMEM/F12, B27 supplement (Gibco BRL) and growth factors bFGF (20 ng/ml; Peprotech), 
EGF (20 ng/ml; Peprotech), LIF (20 ng/ml, Chemicon) and gentamicin (Gibco BRL). The 
stem/progenitor cells were grown as neurospheres, the medium was changed every three 
days, the spheres were dissociated by mechanical trituration after every 12-15 days. 
Glioblastoma biopsy materials (obtained from Dr E.Jõeste, Department of Pathology, North-
Estonian Regional Hospital, Tallinn) were from patients who had signed a consent form. 
Materials were manipulated by the same method as in the isolation of CNS stem/progenitor 
cells. The isolation of both CNS stem/progenitor cells and neurosphere-like growing cells 
from glioblastoma biopsies were performed earlier in LabAs Ltd. In this study five neural 
stem/progenitor cell lines (hBrSc003, hBrSc004, hBrSc005, hBrSc006 and hBrSc009) and two 
glioblastoma spheric cell lines (glioblastoma TiVi M-cells and glioblastoma OtAi M-cells) were 
used for the development and characterization of new monoclonal antibodies (Fig. 2). During 
differentiation all these cell lines produced three main neural cell types: neurons, astrocytes 
and oligodendrocytes as it was shown by staining cells with ǃ-III-tubulin, GFAP and GalC 
(Fig. 3) although in glioblastoma spheroid cultures the cellular and nuclear heterogeneity was 
significantly higher than in fetal neural stem cell cultures (unpublished). Differentiation of fetal 
neurospheres and neurosphere-like growing glioblastoma cells (spheroids) was initiated by 
plating cells onto laminin-coated cover-glasses in the growth media containing all-trans 
retinoic acid (RA; 10-6 M) and dibutyryl cyclic AMP (dBcAMP; 1mM) and the cells were fixed 
on different days after the initiation of differentiation. 
 
Fig. 2. Neurospheres in fetal neural stem/progenitor cell lines (hBrSc004, hBrSc005 and 
hBrSc006) and spheroids in glioblastoma OtAi ”M” and TiVi ”M” cell lines. The last picture 
shows a clone of TiVi M culture, adapted to grow on surface (Inverted microscope, obj. 
LWD A20PL 0.40 160/1.2). 
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Fig. 3. Expression of different neural immunomarkers in fetal neural stem/progenitor cell 
line hBrSc006. Neurospheres were differentiated for 7 days. Cells were fixed with 4% PFA 
and permeabilized with Tritone X-100. (A) Double staining for ǃ-III-tubulin (green – Alexa 
488) and GFAP (red – Alexa 594); (B) Double staining for ǃ-III-tubulin (green – Alexa 488) 
and GalC (red – Alexa 594); (C) Double staining for GFAP (green – Alexa 488) and GalC (red 
– Alexa 594), note co-location of GFAP and GalC – yellow staining. Obj. 40x. DAPI is used 
for nuclei staining (blue). 
3.2 Development of new mouse monoclonal antibodies 
3.2.1 Preparation of immunogen 
The three neural stem/progenitor cell lines (hBrSc003, hBrSc004 and hBrSc005) and one 
glioblastoma spheric cell line (glioblastoma TiVi M-cells) were used as immunogens in this 
study. The stem/progenitor cells were grown as neurospheres, the DMEM/F12 medium 
with B27 supplement (Gibco BRL) and growth factors bFGF (20 ng/ml; Pepro Tech, 
Princeton, USA), EGF (20 ng/ml; Pepro Tech, LIF (20 ng/ml, Chemicon, Temecula, USA) 
and gentamicin (Gibco BRL) was changed every 3 days. Two-three-week old neurospheres 
from one 25cm2 cell culture flask were mechanically dispersed into cell suspension and 
thereafter repeatedly frozen and thawn to get cell fragments. 
3.2.2 Development of mouse hybridoma cells 
About 100 μl of the disrupted cell suspension were injected intraperitoneally into 6-week-
old normal female Balb/c mice. The injections were repeated 4 times at 4-week intervals.  
The cells from the spleens of immunized Balb/c mice were fused with the Sp2/0 myeloma 
cells by standard procedure (Mikelsaar et al., 2009). Hybridomas were grown in the RPMI 
1640/HAT medium containing 10% FCS (Gibco BRL) and gentamicin. Primary screening of 
supernatants from hybridomas was performed starting from the 10th day of growth. Both 
unfixed and/or non-permeabilized paraformaldehyde (PFA) fixed human fetal 
stem/progenitor cells were tested immunocytochemically for the reaction with MAbs. The 
unfixed cells were incubated with hybridoma supernatants for 1 h at 37°C or overnight at 4°C, 
washed three times with PBS and a specific reaction of the MAb was revealed by incubating 
cells with fluorochrome ALEXA 594® - conjugated secondary goat anti-mouse IgG antibody 
(Molecular Probes, Eugene, USA) for 1 h. The cell fixation without permeabilization was 
performed with 8% PFA in PBS for 15 min at room temperature (RT), washed three times with 
PBS, the excess of aldehyde being quenched with 50mM NH4Cl in PBS (10 min) and blocked 
(0.3% casein, 0.01% Tween 20 in PBS) for 1 h at RT or overnight at 4°C. Ice-cold 100% methanol 
producing permeabilization was used for a further characterization of MAbs. The cells were 
incubated for 15 min at RT, washed three times with PBS and blocked. From plenty of MAb-
producing clones, only those that revealed heterogeneity of reaction with stem/progenitor 
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cells, and glioblastoma spheroid cultures, were further investigated. The expression of 
antigens of selected monoclonal antibodies was further characterized besides neural 
stem/progenitor cells also on other living and/or fixed cells of different origin. It is important 
to find the cells where the target antigen of MAbs has the strongest expression in order to use 
these cells for molecular characterization of the antigen. 
3.2.3 MAb cloning and isotyping 
Selected hybridomas were cloned by limiting dilution and isotypes of the MAbs were 
determined by using goat anti-mouse Ig isotype specific antibodies developed in LabAs Ltd 
Cloned hybridomas are stored in a liquid nitrogen cell bank. 
3.3 Immunocytochemical characterization of monoclonal antibodies 
3.3.1 Cells and cell lines used to characterize monoclonal antibodies 
Besides the cells used as immunogens (fetal neural stem/progenitor and glioblastoma 
spheroid cells) other types of cells and cell lines were used to characterize monoclonal 
antibodies. This was necessary to study the specificity of antibodies and is also useful to find 
out the positive cell lines with shorter duplication time. These cell lines were often used for 
getting more cellular material in shorter time for the identification of target antigens of 
MAbs (see also 3.4.2). The following additional cells and cell lines were used for the 
characterization of monoclonal antibodies: normal human cells - human blood 
thrombocytes, human sperms, normal fetal and adult skin fibroblast cell lines NL011 (LabAs 
Ltd) and SA-54, respectively, human normal amniotic epithelial cell line KM (LabAs Ltd.); 
malignant cell lines - human glioblastoma TiViMNBFCS10 cell line, glioblastoma TiVi M 
clone 16, glioblastoma OjArMNBFCS and OjFeMNBFCS cell lines (all developed in LabAs 
Ltd), Bowes melanoma cell line; cells of other species - COS-1 cell line (simian origin), rat 
granulare cell culture (kindly provided by Prof. A. Žarkovsky). 
3.3.2 Fixation methods 
Paraformaldehyde or methanol fixation methods were used. In PFA fixation the coverslips 
were transferred without any previous washing into dishes containing prewarmed 4% PFA 
in PBS and left for 5 min at RT. Then the coverslips were washed for 3x 5 min with PBS and 
the excess of aldehyde was quenched with 50mM of NH4Cl in PBS (10 min). After washing 
twice with PBS, the cells were permeabilized for 10 min with 0.1% Tritone X-100 in PBS, 
washed with PBS and blocked. (In methanol fixation the coverslips were treated for 5 min 
with ice cold methanol and washed with PBS). The coverslips were then transferred into a 
blocking solution (0.3% casein, 0.01% Tween 20 in PBS) for 1 h at RT or overnight at 4°C. 
3.3.3 Staining methods 
The blocking solution was removed by aspiration and the cells were stained as follows: they 
were incubated for 1 hour at RT with the MAb supernatant. The coverslips were washed at 
least for 3x5 min with PBS and immunolabeling was visualized by incubating the cells with 
the goat anti-mouse IgG antibody conjugated with fluorochrome Alexa 594 (Molecular Probes) 
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for 1 h at RT. In all cases, the coverslips were washed at least for 3x5 min with PBS, 10 µl of 
DAPI solution 1μg/ml was added into the last PBS and then the coverslips were incubated for 
5 minutes at RT. After quick rinsing in distilled water, the coverslips were mounted in the anti-
fading mounting medium Prolong Gold Antifade (Molecular Probes). The cells were checked 
by a visual microscoping system (Olympus BX, using objectives UplanFI 20x/0.50, 40x/0.75, 
or 100x/1.30 Oil Iris and the Olympus DP50-CU Photographing System). 
3.4 Characterization and identification of target antigens of new monoclonal 
antibodies 
3.4.1 Strategy for target antigen identification 
Our strategy for the identification of target antigens of monoclonal antibodies was the 
following: (1) lysing , electrophoresis and the immunoblotting of suitable cellular material 
were performed to identify where the bands reacting with specific monoclonal antibodies 
are located; (2) for immunoprecipitation antibodies were caught to protein-G-conjugated 
Sepharose beads from the culture medium or used DVS-activated beads for purified 
antibodies; (3) the immunoprecipitated antigen was separated from the antibody and 
nonspecifically associated material by using electrophoresis in the SDS-PAGE gel; (4) the 
bands containing antigen were identified by using immunoblotting from the same gel; (5) 
the bands containing the antigen were cut out from the gel and trypsinized; (6) tryptic 
peptides and target antigens were identified with aid of mass-spectroscopy (LC ESI-MS-MS) 
and protein databases. 
3.4.2 Cells and cell lines used for identification of target antigenes 
For molecular identification of the target antigens of MAbs different cells and cell lines were 
used (see also 3.3.1). However, in this study mainly the Bowes melanoma cell line (neural 
crest origin) and glioblastoma cell line TiViMNBFCS10 (glioblastoma TiVi M spheroid 
culture, but adapted to growing on the surface) were used. Both the cell lines were 
propagated in medium DMEM/F12 with 10% FCS and gentamicin (Gibco BRL). 
3.4.3 Purification of antigens 
3.4.3.1 Purification of antigens from cells growing on surface 
The cells of the human Bowes melanoma or TiViMNBFCS10 cell lines were lysed in 8M 
urea, 3% SDS, 50mM Tris-HCL, pH 6.8 and diluted with 30 volumes of TBS. About 50 μl of 
Sepharose-bound MAbs were added to 30 ml of the diluted sample solution and incubated 
overnight at 4°C. The beads were washed, incubated in an electrophoresis sample buffer for 
10 min at 95°C and loaded onto the top of the 10% SDS-PAGE gel. After electrophoresis 
immunopositive bands were located by immunoblotting an one part of the gel, whereas the 
rest of the gel was stained with colloidal Coomassie G-250 for the confirmation of protein 
location. This electrophoresis step was absolutely necessary to avoid interferences with non-
specifically bound proteins. The immunopositive band was cut out, minced, washed and 
dried (about 15 min at RT) by CentriVac. The dried pieces of the gel were rehydrated and 
the proteins trypsinized overnight at 37°C with sequencing grade trypsin (Promega, 
Madison WI, USA). 
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3.4.3.2 Purification of human blood thrombocytes 
Purification of platelets was performed essentially according to the method of P.J. Canvar and 
co-workers (Canvar et al., 2007). Shortly, human platelet-rich plasma from the blood center of 
Tartu University Clinicum was further purified by centrifuging at 1400g for 15 min to pellet 
any remaining white or red blood cells and the platelet-rich plasma was decanted. Protease 
inhibitors (Roche Complete, Roche Diagnostics GmbH, Mannheim, Germany) were added as 
recommended by manufacturer and incubated 10 min at RT. Platelets were pelleted by 
centrifuging in at 4°C and washed once in Tyrode’s buffer by centrifuging at 2400g for 15 min 
at 4°C. The pellets were stored in Tyrode’s buffer at -80°C until used. 
3.4.3.3 Cell lysis 
Radioimmunoprecipitation assay buffer (RIPA) was used containing 50 mM of Tris/HCl pH 
7.4 (ultrapure, AppliChem, Darmstadt, Germany); 0.1% SDS (ultrapure, AppliChem, 
Darmstadt, Germany); 1% NP40 (Octylphenoxy polyethoxy ethanol, reagent grade, 
AMRESCO, Solon Ind. Ohio, USA); 1% Tritone X-100 (Schuchardt, München, Germany); 
0.5% DOC (Natriumdeoxycholat, AppliChem, Darmstadt, Germany); 500 mM NaCl 
(AppliChem, Darmstadt, Germany); protease inhibitor tablets (Roche Complete, Roche 
Diagnostics GmbH, Mannheim, Germany). For more gently lysis of the cells simply 1%NP40 
solution in PBS (AppliChem, Darmstadt, Germany) was used. 
3.4.3.4 SDS-polyacrylamid gel electrophoresis (SDS-PAGE)  
Cells for electrophoresis were lysed in the RIPA buffer or with 1% NP-40 in PBS and 
centrifuged at maximum speed in Eppendorf centrifuge 5415C for 10 min at 4°C. The 
supernatant was diluted 1:1 in the SDS-electrophoresis sample buffer with DTT (AppliChem, 
Darmstadt, Germany) and heated for 10 min at 95°C or at 60°C for sensitive antigenes. Before 
electrophoresis 8M of urea was added to the sample solution until 2M of the end 
concentration. Electrophoresis was run in a mighty small Hoefer electrophoresis system 
(Hoefer Scientific Instruments, CA, USA) with the glasses of 10 x 12 cm and the spacers of 0.75 
mm. The end concentration of the gel buffer was 0.43 M and pH 8.4. Usually the samples were 
separated in the gradient (8-24%) SDS-PAGE gel for achieving sharper bands, yet the 
concentrating gel was not used. The parameters for prerunning electrophoresis were 60 V and 
30 min. Electrophoresis was run for 4 hours at max 210V and 16mA. 
3.4.3.5 Colloid Coomassie G250 staining 
Colloid Coomassie G250 staining was performed essentially according to the D.Kang and 
co-workers (Kang et al., 2002). Shortly, the SDS-PAGE gel was fixed in a mixture of 30% 
ethanol and 2% phosphoric acid for 15 min and washed in distilled water 3x for 15 minutes. 
Staining was performed in a solution containing 5% w/v aluminium sulphate (Applichem, 
Darmstadt, Germany), 0.02% Coomassie G-250 (Serva Electrophoresis GmbH, Heidelberg, 
Germany), 2% phosphoric acid and 10% ethanol for 1 hour. Destaining was performed in 
distilled water until the bands became clearly visible. 
3.4.3.6 Western blot 
The method described in the Millipore manual for immunoblotting to the PVDF membrane 
was used. Buffer components and the stain were from AppliChem, Darmstadt, Germany. 
The procedure was as follows: the membrane was wetted in methanol for 1 to 3 seconds. 
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Methanol was eluted incubating the membrane for 5 min in distilled water on a shaker. 
Thereafter the membrane was equilibrated in the transfer buffer for 2 to 3 min. SDS-PAGE 
gel was equilibrated in the cathode buffer for 15 min on the shaker. GEHealthcare 
electrophoresis unit Multiphor II and a semidry immunoblotting kit for electroblotting were 
used. The anode buffers were Tris 0.3 M (no.1) and Tris 15 mM (no.2); the cathode buffer 
contained 40 mM of glycine and 25 mM of Tris. Two sheets of chromatography papers 
(Whatman CHR17, Mainstone, England) were soaked in anode buffer no.1 and one sheet in 
the anode buffer no.2. The wetted PVDF membrane was placed on the top of the soaked 
anode sheets and then equilibrated SDS-PAGE gel was placed on the top of them. After that 
three chromatography papers with the cathode buffer were located on the top of the gel and 
immunoblotting was performed at 0.8 mA /cm2 for 2 hours. After electroblotting nonspecific 
binding of antibodies was blocked by incubating the membrane in TBS with 0.1% Tween 20 
(Sigma, MO, USA). For vimentin-specific antibody GB26 10G3 a mixture of 1% horse serum 
and 0.1% Tween 20 in TBS was used as a blocking solution. The membrane was incubated 
with monoclonal antibody in the blocking buffer for overnight at 4°C. After washing 3 x for 10 
min in PBS 0.1% Tween 20 the membrane was incubated with a secondary antibody (goat anti-
mouse IgG polyclonal antibody conjugated with horseradish peroxidase) in PBS 0.1% Tween 
20 for one hour at RT. After that the membrane was washed with 0.1% Tween 20 in PBS 3 
times for 10 min and then 1 x for 10 min in PBS. The membrane was incubated for 10 minutes 
in the staining solution containing 50 mg of DAB (diaminobenzidin trihydrochloride, 
AppliChem, Darmstadt, Germany), 6 ml chloronaphtole (Sigma, MO,USA) solution (3 mg/ml) 
in ethanol and 20 µl of 30% H2O2 in PBS and washed 3 times for 5 minutes in distilled water. 
After drying the membrane can be saved in the archive. 
3.4.3.7 Conjugation of antibody with horseradish peroxidase 
Antibodies were conjugated to HRP as described previously (Tjissen, 1985). Shortly, 1 mg of 
horseradish peroxidase (Boehringer Mannheim, Germany) was solubilized in the Eppendorf 
tube in 0.1 ml of the freshly prepared 0.1M NaHCO3 solution and 0.1 ml of 8-16 mM NaIO4 
(Merck, Darmstadt, Germany) was added and incubated for 2 hours in the dark room at RT. 
3 mg of antibody was solubilized in 1 ml of the sodium carbonate buffer pH 9.2 and dry 
Sephadex G-25 (GE Healthcare, Sweden) was added of about 1/6 from the total amount of 
the solution and the mix was incubated for 3 hours in the dark room at RT. The conjugate 
was eluted from Sephadex and mixed (1/20 from the total volume) with the freshly 
prepared NaBH4 (Sigma, MO, USA) solution in 0.1M of NaOH (5 mg/ml) on a shaker. After 
30 min an additional amount of the NaBH4 solution (1/10 from the total volume) was added 
and the mix was incubated for 1 hour at 4°C. Then 50% of glycerol (AppliChem, Darmstadt, 
Germany) was added and the conjugate was stored at -20°C. For immunoblotting HRP-
conjugated antibodies were diluted from 1:500 to 1:1500. 
3.4.3.8 Activating of Sepharose granules with divinylsulphone (DVS) and binding of 
antibodies to activated granules 
Sepharose CL-4B granules (Pharmacia, Uppsala, Sweden) were washed with distilled water 
of 4 to 5 gel volumes. The granules were equilibrated with 4 to 5 gel volumes of 0.5 M 
carbonate buffer (pH 11), 10 ml of the 0.5 M carbonate buffer (pH 11) containing 1 ml of 
divinylsulphone (Sigma, MO, USA) were added to 10 ml of the gel and incubated on a 
shaker for 1.5 hr. The activated granules were washed once with the carbonate buffer, then 2 
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x with distilled water and stored in PBS with 0.01% NaN3 at 4°C. Activated granules are 
useable during about 1 year. For the binding of antibodies the granules were washed with 4 
to 5 volumes of distilled water and then equilibrated in 0.1 M carbonate buffer pH 9.0. The 
buffer for antibodies was changed to the carbonate buffer pH 9.0 using the PD 10 column 
(GE Healthcare, Sweden). DVS-activated Sepharose CL-4B granules (200 µl) were added to 
antibody solution (1-2 mg in 3.5 ml) in the carbonate buffer and incubated for 10 min at RT. 
Then 5% PEG 20,000 was added and the granules were incubated overnight at RT on a 
shaker. Afterwards the granules with conjugated antibodies were washed and blocked in 
TBS buffer and stored in TBS at 4°C with 0.01% NaN3 until used. 
3.4.3.9 Immunoprecipitation 
For immunoprecipitation the lysates in RIPA buffer, PBS with 1%NP40 or PBS/TBS diluted 
1:30 electrophoresis sample buffer were used. Before immunoprecipitation MAbs from 1.5 
ml of the hybridoma medium (sometimes more) were conjugated to 50 µl of Protein-G 
Sepharose 4 Fast Flow granules (GE Healthcare, Sweden). The granules were washed 3 
times in the immunoprecipitation buffer and incubated with cell lysate at 4°C overnight. 
Then the granules were washed in one of the immunoprecipitation buffers 4 times and once 
with distilled water. The washed granules (50 µl) were diluted in 150 µl of the SDS-PAGE 
sample buffer and incubated for 5 min at 95°C or in case of sensitive antigenes for 10 min at 
60°C. Then 50 µl of 8M urea were added and the granules were incubated for 15 min at RT 
on a shaker and thereafter put on the top of the electrophoresis gel. When purified 
monoclonal antibodies not hybridoma supernatants were used for immunoprecipitation, 
MAbs were directly conjugated to the divinyl-sulphone-activated granules. 
3.4.3.10 Trypsinization of isolated antigenes 
After electrophoresis, immunopositive bands were located by immunoblotting a part of the 
gel, whereas the rest of the gel was stained with colloidal Coomassie G-250 for the 
confirmation of protein location. This electrophoresis step is necessary to avoid interferences 
with non-specifically bound proteins. The immunopositive band was cut out from the gel 
and minced to pieces of about 1 x 1 mm using a scalpel. Pieces of the gel were washed once 
with methanol on a shaker for 1-2 minutes, then with 10 mM (NH4 )2CO3 2 times for 5 min 
and thereafter with 50% acetonitrile in 10 mM (NH4 )2CO3. The gel pieces were dried with 
the CentriVac for 15 min and treated for 10 min with the solution containing 2µg of trypsine 
in 1 ml of 50 mM (NH4 )2CO3 with 0.05% ProteasMax surfactant (Promega, USA). 10 mM of 
(NH4)2CO3 was added to fully coated gel pieces and incubated at 37°C overnight. The 
solution from the top of the gel and the washing solutions were collected into one tube. The 
gel pieces were washed two times with 50% acetonitrile in 10 mM (NH4 )2CO3 and once in 
pure acetonitrile. The solution containing peptides was concentrated until the amount of 100 
µl and analyzed using mass-spectroscopy. Sometimes for confirming the exact band location 
in the gel direct staining of proteins on the membrane is needed. To that end colloid 
Coomassie stain diluted 1:1 in distilled water was used. After that we destained the 
membrane washing with distilled water about ten times 10 min or until protein bands 
became visible. On the dry membrane we saw strongly stained black bands containing the 
antigen or antibody components and other blue-stained bands containing different co-
immunoprecipitated nonantigenic proteins. 
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3.4.3.11 Peptide analysis by LC ESI-MS/MS and protein identification with Mascot and 
the Global Proteome Machine 
The Agilent 1100 Series chromatograph with LC/MSD Trap XCT (Agilent, Santa Cruz, USA) 
was used for LC/MS experiments applying the 2.1 x 150 mm Agilent 300Extend C18 column 
of 3.5 μm particle size. 50 μl of the peptide mixture was injected into the column and eluted 
with a gradient from 0.1% HCOOH/5% acetonitrile to 75% acetonitrile during 120 minutes 
at 0.3 ml/min. The column was thermostated at 35˚C. Positive ions were detected in a 
“smart mode” with the target mass set to 1000 m/z, whereas doubly charged ions were 
preferred. The data were analyzed with both Mascot www.matrixscience.com and GPM 
www.thegpm.org search engines (1000 most abundant ions). For the positive identification 
of the antigen the consent of both search engines was necessary. 
4. Results 
During our study we have developed several hundreds of new monoclonal antibodies. The 
characterization and identification of the target antigens of them are in progress. Some 
results of this work have been recently published (Mikelsaar et al., 2009). Here we present 
data on the five new monoclonal antibodies (see Table 1), which we have developed 
according to the strategy described in this chapter. 
 
Name of 
monoclonal 
antibodies 
Ig sub- 
class 
Immunogen Identified 
target 
antigen 
Neural cell types identified by 
antibody 
E14G2 IgG1 Mix of fetal neural 
cell lines hBrSc003/ 
hBrSc004/ hBrSc005
Annexin A1 Annexin A1- and + cells among 
differentiated fetal neural stem cells, 
glioblastoma spheroid cells and in 
glioblastomas;  microglia; annexin 
A1+ glial cells and Purkinje (?) cells 
in rat granule cell culture 
E15F10.B9 IgG1 Mix of fetal neural 
cell lines hBrSc003/ 
hBrSc004/ 
hBrSc005 
Calnexin Calnexin- and + cells among 
differentiated fetal neural stem 
cells and glioblastoma spheroid 
cells; shows cellular heterogeneity 
in glioblastomas 
W4A8.F4 Ig2a hBrSc003 14-3-3 ζ/δ Both human and rat glial and 
neuronal cells 
GB26 10G3 IgG1 Mix of  
different glioblas- 
toma cells  
Vimetin The precursors cells of both 
neuronal and glial lineages; shows 
cellular heterogeneity in 
glioblastomas 
A3G2.B4 IgG1 hBrSc003 Lupus La 
protein 
La protein- and + cells among 
differentiated fetal neural stem 
cells and glioblastoma spheroid 
cells; shows cellular heterogeneity 
in glioblastomas 
Table 1. Summary of new monoclonal antibodies described in this chapter. All these 
antibodies may be useful for detailed analysis of the expression of target antigens in all 
types of neural cells .  
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4.1 New monoclonal antibodies 
4.1.1 Monoclonal antibody E14G2 (MAb E14G2) 
Here we describe the results of the immunocytochemical analysis of MAb E14G2 (Table 1) 
with different cell types and the biochemical/molecular analysis for identifying the target 
antigen of the antibody. In Fig. 4 we can see a distinct heterogenous expression of MAb 
E14G2 antigen in differentiated fetal neural stem/progenitor (A,B,C,D), in glioblastoma 
spheroid cells (E) and also in the rat granule primary culture (H). However, the expression 
of the target antigen of MAb E14G2 was strong and homogenous in glioblastoma OjAr 
secondary culture and in Bowes melanoma cell lines (F and G, respectively). 
 
 
 
 
Fig. 4. Presence of MAb E14G2 target antigen (Annexin A1) in different cells. (A) Human 
fetal hBrSc003 neurosphere cells differentiated for 11 days. Double immunofluorescent 
staining, cells were fixed with 4% PFA and permeabilized. Annexin A1 expression was 
revealed by red staining – Alexa 594, ǃ-III-tubulin by green staining – Alexa 488, obj. 40x. (B-
D). Human fetal hBrSc005 neurosphere cells differentiated for 3 days (B,C) and 7 days (D). 
Double immunofluorescent staining, cells were fixed with 4% PFA and permeabilized. 
Annexin A1 expression was revealed by red staining – Alexa 594, ǃ-III-tubulin by green 
staining – Alexa 488, obj. 40x. (E) Human glioblastoma TiVi spheroid cell line differentiated 
for 7 days. Double immunofluorescent staining, cells were fixed with 4% PFA and 
permeabilized. Annexin A1 expression was revealed by red staining – Alexa 594, ǃ-III-
tubulin by green staining – Alexa 488, obj. 40x. (F) Human glioblastoma OjAr secondary cell 
culture on the 6th day of cultivation. Cells were fixed with 4% PFA and permeabilized. 
Annexin A1 expression was revealed by red staining – Alexa 594, obj. 40x. (G) Bowes 
melanoma cell line on the 2nd day of cultivation, fixed with 4%PFA, no permeabilization. 
Specific Annexin A1 staining was revealed by red staining – Alexa 594, obj. 40x. (H) Rat 
granulare cell culture. Double immunofluorescent staining, cells were fixed with 4% PFA 
and permeabilized. Annexin A1 expression was revealed by red staining – Alexa 594, GFAP 
by green staining – Alexa 488, obj. 100x. DAPI is used for nuclei staining (blue). 
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Fig. 5. Electrophoresis and Western blot of MAb E14G2 target antigen. (1) negative control, 
MAb Y1C7 directly conjugated with peroxidase; (2) MAb E14G2 directly conjugated with 
peroxidase; (3) gel stained with colloid Coomassie G-250. Arrows with numbers indicate 
bands analyzed by LC ESI-MS/MS. 
In Fig. 5 we present the data on electrophoresis and immunoblot of the target antigen of 
MAb 14G2. The antigen was immunoprecipitated from the Bowes melanoma cell lysate and 
the precipitated cells (100 μl) were lysed in 10 ml of RIPA buffer. MAb E14G2 was 
conjugated directly to the divinylsulphone-activated Sepharose granules. Then 50 µl of the 
activated granules were incubated in 10 ml of the cleared Bowes melanoma cell lysate 
overnight at 4°C, washed 4x with the buffer and 1x with distilled water. Then 150 µl of SDS-
PAGE sample buffer was added and the sample heated 5 min at 95°C before electrophoresis. 
The bands, which were positive according to the reaction with specific monoclonal antibody 
MAb E14G2 (Fig. 4, arrows 213-216) were analyzed by LC ESI-MS/MS and the proteins 
were identified using Mascot and the GPM software databases (see Table 2). 
 
Band Identified proteins Mass Mascot 
score 
Sequence 
coverage 
% 
213 ANXA1 - Annexin A1 
KV401 - Ig kappa chain V-IV region  
38690 
13372 
41 
37 
8 
7 
214 ANXA1 - Annexin A1 38690 2274 71 
215 ANXA1 - Annexin A1 
TBB5 - Tubulin beta chain 
K2C1- Keratin, type II cytoskeletal 1 
38690 
49639 
65999 
198 
113 
84 
34 
24 
6 
216 DHSA- Succinate dehydrogenase 
[ubiquinone] flavoprotein subunit, mit  
K2C1- Keratin, type II cytoskeletal 1 
ANXA1 - Annexin A1 
72645 
 
65999 
38690 
103 
 
82 
65 
26 
 
7 
18 
Table 2. LC ESI-MS/MS and Mascot software analysis of immunoprecipitated with MAb 
14G2 proteins in bands 213, 214, 215 and 216 (Fig. 4, arrows 213-216). 
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  1 MAMVSEFLKQ AWFIENEEQE YVQTVKSSKG GPGSAVSPYP TFNPSSDVAA 
 51 LHKAIMVKGV DEATIIDILT KRNNAQRQQI KAAYLQETGK PLDETLKKAL 
101 TGHLEEVVLA LLKTPAQFDA DELRAAMKGL GTDEDTLIEI LASRTNKEIR 
151 DINRVYREEL KRDLAKDITS DTSGDFRNAL LSLAKGDRSE DFGVNEDLAD 
201 SDARALYEAG ERRKGTDVNV FNTILTTRSY PQLRRVFQKY TKYSKHDMNK 
251 VLDLELKGDI EKCLTAIVKC ATSKPAFFAE KLHQAMKGVG TRHKALIRIM 
301 VSRSEIDMND IKAFYQKMYG ISLCQAILDE TKGDYEKILV ALCGGN   N 
Fig. 6. Amino acid sequences of Annexin A1, ANXA1. In red are marked amino acids 
sequences identified by mass-spectroscopy (band 214 in Fig. 5). 
Conclusion 
On the basis of data presented above we conclude that the target antigen of MAb E14G2 is 
protein Annexin A1. According to UniProtKB/Swiss-Prot database Annexin A1 is a 
calcium/phospholipid-binding protein which promotes membrane fusion and is involved 
in exocytosis. This protein regulates phospholipase A2 activity.  
(http://www.uniprot.org/uniprot/P04083#section_comments). 
 
Fig. 7. Presence of MAb E15F10.B9 target antigen (calnexin) in different cells. (A) Human 
fetal hBrSc003 neurosphere cells differentiated for 11 days. Double immunofluorescent 
staining, cells were fixed with 4% PFA and permeabilized. Calnexin expression was 
revealed by red staining – Alexa 594, ǃ-III-tubulin by green staining – Alexa 488, obj. 40x. (B) 
Human fetal hBrSc003 neurosphere cells differentiated for 7 days, cells were fixed with 4% 
PFA and permeabilized. Calnexin expression was revealed by red staining – Alexa 594, obj. 
100x. (C) Human glioblastoma TiVi spheroid cell line differentiated for 7 days. Double 
immunofluorescent staining, cells were fixed with 4% PFA and permeabilized. Calnexin 
expression was revealed by red staining – Alexa 594, ǃ-III-tubulin by green staining – Alexa 
488, obj. 40x. (D) Human normal amniotic epithelial cell line KM on the fifth days of 
cultivation. Double immunofluorescent staining, cells were fixed with 4% PFA and 
permeabilized. Calnexin expression was revealed by red staining – Alexa 594, actin by green 
staining with Alexa 488 conjugated Phalloidin, obj. 100x. (E) Unfixed cells of adult skin 
fibroblast cell line SA-54 on the 3rd day of cultivation. Specific calnexin staining revealed by 
green staining – Alexa 488, obj. 20x. (F) Human glioblastoma TiViMNBFCS10 cells on the 
3rd day of cultivation, fixed with 4%PFA, no permeabilization. Specific calnexin staining 
revealed by red staining – Alexa 594, obj. 100x. (G) Bowes melanoma cell line on the 2nd day 
of cultivation, fixed with 4%PFA, no permeabilization. Specific calnexin staining revealed by 
red staining – Alexa 594, obj.100x. (H) Unfixed sperms of a normal human male. Specific 
calnexin staining revealed by red staining – Alexa 488, obj. 100x (note a red staining between 
the sperm head and tail). DAPI is used for nuclei staining (blue). 
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4.1.2 Monoclonal antibody E15F10.B9 (MAb E15F10.B9) 
In Fig. 7 we can see different expression of MAb E15F10.B9 (Table 1) detected antigen in 
differentiated fetal neural stem/progenitor (A) and glioblastoma spheroid cells (C). In some 
regions of hBrSc003 cell line differentiated for 7 days there was a very strong expression of 
MAb E15F10.B9 target antigen (B). Strong expression of the antigen one can see also in 
unfixed adult skin fibroblasts and in fixed, but not permeabilized glioblastoma and Bowes 
melanoma cells. Interestly, in unfixed human sperms the staining of MAb E15F10.B9 was 
seen as two separate points between the head and neck of the sperm (H). Double staining 
with actin in normal amniotic epithelial cells (D) shows an independent staining of actin and 
target antigen of MAb E15F10.B9, whereas the last one shows nuclear membrane and 
punctate cytoplasma staining. 
The LC ESI-MS/MS and Mascot database analysis of peptides from the immunoprecipitated 
band 208 (Fig. 8) identified two possible candidates for the target antigen of MAb E15F10.B9 
– calnexin and Keratin, type II cytoskeletal 1. However, as immunocytochemical analysis on 
different cell types including normal epithelial amniotic cells (Fig. 7) showed no typical 
cytoskeletal staining for cytokeratin we consider the keratin to be in immunoprecipitate as a 
contaminant substance. In Fig. 8 and 9 and Table 3 the results of Western blot and molecular 
identification of the target antigen of MAb E15F10.B9 are shown. 
 
Fig. 8. Western blot of MAb E15F10.B9 target antigen (calnexin). MAb E15F10.B9 from 
hybridoma supernatant was conjugated to Protein G granules and thereafter target antigen 
immunoprecipitated from Bowes melanoma cell line lysed with RIPA buffer. Proteins were 
separated in SDS-PAGE 4-12% gradient gel. (1) negative control with HRP-conjugated goat 
anti-mouse IgG secondary antibody; (2) incubation with MAb E15F10.B9 and secondary 
antibody. Arrow indicates the band analyzed by ESI-MS/MS. 
Band Identified proteins Mass Mascot 
score 
Sequence 
coverage 
% 
208 CALX - Calnexin 
K2C1- Keratin, type II cytoskeletal 1 
67526 
65999 
384 
313 
22 
20 
Table 3. LC ESI-MS/MS and Mascot software analysis of the proteins in the band which was 
immunoprecipitated with MAb E15F10.B9 proteins (Fig. 8). 
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  1 MEGKWLLCML LVLGTAIVEA HDGHDDDVID IEDDLDDVIE EVEDSKPDTT 
 51 APPSSPKVTY KAPVPTGEVY FADSFDRGTL SGWILSKAKK DDTDDEIAKY 
101 DGKWEVEEMK ESKLPGDKGL VLMSRAKHHA ISAKLNKPFL FDTKPLIVQY 
151 EVNFQNGIEC GGAYVKLLSK TPELNLDQFH DKTPYTIMFG PDKCGEDYKL 
201 HFIFRHKNPK TGIYEEKHAK RPDADLKTYF TDKKTHLYTL ILNPDNSFEI 
251 LVDQSVVNSG NLLNDMTPPV NPSREIEDPE DRKPEDWDER PKIPDPEAVK 
301 PDDWDEDAPA KIPDEEATKP EGWLDDEPEY VPDPDAEKPE DWDEDMDGEW 
351 EAPQIANPRC ESAPGCGVWQ RPVIDNPNYK GKWKPPMIDN PSYQGIWKPR 
401 KIPNPDFFED LEPFRMTPFS AIGLELWSMT SDIFFDNFII CADRRIVDDW 
451 ANDGWGLKKA ADGAAEPGVV GQMIEAAEER PWLWVVYILT VALPVFLVIL 
501 FCCSGKKQTS GMEYKKTDAP QPDVKEEEEE KEEEKDKGDE EEEGEEKLEE 
551 KQKSDAEEDG GTVSQEEEDR KPKAEEDEIL NRSPRNRKPR RE       E 
Fig. 9. Amino acid sequences of Calnexin. With red colour are marked amino acids 
sequences identified by mass-spectroscopy (band 208 in Fig. 8). 
Conclusion 
On the basis of data presented above we conclude that the target antigen of MAb E15F10.B9 
is protein Calnexin. According to UniProtKB/Swiss-Prot database Calnexin is a calcium-
binding protein that interacts with newly synthesized glycoproteins in the endoplasmic 
reticulum. It may act in assisting protein assembly and/or in the retention within the ER of 
unassembled protein subunits. It seems to play a major role in the quality control apparatus 
of the ER by the retention of incorrectly folded proteins (http://www.uniprot.org/ 
uniprot/P27824). 
 
 
 
Fig. 10. Presence of MAb W4A8.F4 target antigen (protein 14-3-3) in different cells. Specifc 
staining of  MAb W4A8.F4 was revealed by red staining –Alexa 594. (A,B) Human fetal 
hBrSc006 (A) and hBrSc009 (B) neurosphere cells differentiated for 3 days. Cells were fixed 
with 4% PFA and permeabilized, obj. 100x. (C) Human fetal skin fibroblast culture on the 
3rd day of cultivation. Cells were fixed with 4% PFA and permeabilized, obj. 100x. (D) 
Unfixed sperms of a normal human male, obj. 100x. (E-F) Human glioblastoma cell line 
TiViMNBFCS10 (E), Bowes melanoma cell line (F), COS-1 cell line and rat granulare cell 
culture (H) on the 3rd day of cultivation. Cells were fixed with 4% PFA and permeabilized, 
obj. 100x. DAPI is used for nuclei staining (blue). 
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4.1.3 Monoclonal antibody W4A8.F4 (MAb W4A8.F4) 
In Fig. 10 we can see the expression of MAb W4A8.F4 (Table 1) in the fetal neural 
stem/progenitor cell lines hBrSc006 (A) and hBrSc009 (B). The strong staining was seen in 
the cytoplasm in Golgi region but also in cell projections and nuclei. In the fetal skin 
fibroblasts, glioblastoma, Bowes melanoma and COS-1 cell lines the cytoplasm, especially 
Golgi region was strongly stained (C,E,F and G respectively). In the rat granulare cell 
culture there was a heterogeneous staining of the cytoplasm and nuclei (H). Interestly, in the 
unfixed human sperms the entire tail, except the neck, was strongly and homogeneously 
stained (D). 
In Fig. 11 and 12 and Table 4 the results of Western blot and molecular identification of the 
target antigen of MAb W4A8.F4 are shown. 
 
 
Fig. 11. Western blot with MAb W4A8.F4. Proteins in RIPA lysate were separated 
electrophoretically in SDS-PAGE gradient (8-25%) gel and transferred to PVDF membrane: 
(1) Bowes cell line, (2) glioblastoma TiViMNBFCS10 cell line and (3) human thromocytes. I – 
negative control with HRP-conjugated goat anti-mouse IgG secondary antibody; II – 
reaction with MAb W4A8.F4 and secondary antibody. Arrow indicates the band 157, 
analyzed by ESI-MS/MS. 
Band Identified proteins Mass Mascot 
score 
Sequence 
coverage % 
157 14-3-3 protein zeta/delta 
14-3-3 protein gamma 
14-3-3 protein eta 
14-3-3 protein sigma 
Chloride intracellular channel protein 1 
27728 
28295 
28201 
27757 
26906 
139 
64 
64 
64 
62 
40 
18 
19 
12 
19 
Table 4. LC ESI-MS/MS and Mascot software analysis of immunoprecipitated with MAb 
W4A8.F4 proteins in band 157 (Fig. 11). 
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  1 MDKNELVQKA KLAEQAERYD DMAACMKSVT EQGAELSNEE RNLLSVAYKN 
 51 VVGARRSSWR VVSSIEQKTE GAEKKQQMAR EYREKIETEL RDICNDVLSL 
101 LEKFLIPNAS QAESKVFYLK MKGDYYRYLA EVAAGDDKKG IVDQSQQAYQ 
151 EAFEISKKEM QPTHPIRLGL ALNFSVFYYE ILNSPEKACS LAKTAFDEAI 
201 AELDTLSEES YKDSTLIMQL LRDNLTLWTS DTQGDEAEAG EGGEN    N 
Fig. 12. Amino acid sequences of protein 14-3-3 protein zeta/delta. With red colour are 
marked amino acids sequences identified by mass-spectroscopy (band 157 in Fig. 11). 
Conclusion 
On the basis of data presented above we conclude that most probably the target antigen of 
MAb W4A8.F4 is protein 14-3-3 zeta/delta. According to UniProtKB/ Swiss-Prot database 
protein 14-3-3 zeta/delta is an adapter protein implicated in the regulation of a large 
spectrum of both general and specialized signaling pathways. Binds to a large number of 
partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding 
generally results in the modulation of the activity of the binding partner 
(http://www.uniprot.org/uniprot/P63104). 
4.1.4 Monoclonal antibody GB26 10G3 (MAb GB26 10G3) 
In Fig. 13 we can see the filamentous staining of MAb GB26 10G3 (Table 1) antigen in 
human adult skin fibroblasts (A) and in glioblastoma cell line TiViMNBFCS10 (B). In 
glioblastoma cell lines the staining pattern was very heterogeneous, some cells did not show 
any signs of staining. Double staining for ǃ-III-tubulin and the MAb GB26 10G3 (C) showed 
an independent staining pattern, some cells were double stained, some cells showed only ǃ-
III-tubulin staining and the majority of cells was only MAb GB26 10G3 positive. In D the 
double staining of target antigen of MAb GB26 10G3 and glial fibrillar acid protein (GFAP) 
is shown. Note that the both antigens are located in the same cells, but show an independent 
staining pattern. 
 
Fig. 13. Presence of MAb GB26 10G3 target antigen in different cells. (A,B) Human adult 
skin fibroblast cell line SA-54 (A) and human glioblastoma cell line TiViMNBFCS10 (B) on 
the 3rd day of cultivation. Cells were fixed with 4% PFA and permeabilized. The target 
antigen of MAb GB26 10G3 expression was revealed by green staining – Alexa 488, obj. 
100x. (C) Human glioblastoma cell line TiViMNBFCS10 on the 3rd day of cultivation. 
Double immunofluorescent staining, cells were fixed with 4% PFA and permeabilized. The 
target antigen of MAb GB26 10G3 expression was revealed by green staining – Alexa 488, ǃ-
III-tubulin by red staining – Alexa 488, obj. 100x. (D) Human glioblastoma cell line 
TiViMNBFCS10 on the 3rd day of cultivation. Double immunofluorescent staining, cells 
were fixed with 4% PFA and permeabilized. The target antigen of MAb GB26 10G3 
expression was revealed by green staining – Alexa 488, GFAP by red staining – Alexa 488, 
obj. 100x. DAPI is used for nuclei staining (blue). 
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Fig. 14. SDS-PAGE gradient gel (8-24%) (1) and immunoblot (2) with MAb GB26 10G3. The 
sample was in RIPA buffer insoluble fraction of glioblastoma TiViNBFCS10 cells that was 
heated with SDS-PAGE sample buffer with DTT at 60°C for 10 min and 8M urea was added 
to 2M final concentration. Arrows with numbers indicate bands analyzed by ESI-MS/MS. 
As molecular masses of antibody light chain and vimentin are similar and vimentin binds 
nonspecifically to the secondary antibody, we could not purify vimentin by immuno-
precipitation as we did for other MAbs. Only gradient electrophoresis of lysate and 
immunoblotting were used to separate the target antigen of MAb GB26 10G3. 
In Fig. 14 and 15 and Table 5 the results of electrophoresis, Western blot and molecular 
identification of the target antigen of MAb GB26 10G3 are shown. 
 
Band Identified proteins Mass Mascot 
score 
Sequence 
coverage % 
248 Vimentin 53619 198 39 
249 Glial fibrillar acid protein - GFAP  
Vimentin  
49850 
53619 
135 
123 
32 
28 
250 Actin, cytoplasmic 1 41710 43 14 
Table 5. LC ESI-MS/MS and Mascot software analysis of proteins in bands 248- 250 (Fig. 14).  
  
  1 MSTRSVSSSS YRRMFGGPGT ASRPSSSRSY VTTSTRTYSL GSALRPSTSR 
 51 SLYASSPGGV YATRSSAVRL RSSVPGVRLL QDSVDFSLAD AINTEFKNTR 
101 TNEKVELQEL NDRFANYIDK VRFLEQQNKI LLAELEQLKG QGKSRLGDLY 
151 EEEMRELRRQ VDQLTNDKAR VEVERDNLAE DIMRLREKLQ EEMLQREEAE 
201 NTLQSFRQDV DNASLARLDL ERKVESLQEE IAFLKKLHEE EIQELQAQIQ 
251 EQHVQIDVDV SKPDLTAALR DVRQQYESVA AKNLQEAEEW YKSKFADLSE 
301 AANRNNDALR QAKQESTEYR RQVQSLTCEV DALKGTNESL ERQMREMEEN 
351 FAVEAANYQD TIGRLQDEIQ NMKEEMARHL REYQDLLNVK MALDIEIATY 
401 RKLLEGEESR ISLPLPNFSS LNLRETNLDS LPLVDTHSKR TLLIKTVETR 
451 DGQVINETSQ HHDDLE                                    E 
Fig. 15. Amino acid sequences of Vimentin. With red colour are marked amino acids 
sequences identified by mass-spectroscopy (band 248 in Fig. 14.). 
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Conclusion 
On the basis of data presented above we conclude that the target antigen of MAb GB26 10G3 
is protein Vimentin. According to UniProtKB/Swiss-Prot database vimentins are class-III 
intermediate filaments found in various non-epithelial cells, especially mesenchymal cells 
(http://www.uniprot.org/uniprot/P08670). 
4.1.5 Monoclonal antibody A3G2.B4 (MAb A3G2.B4) 
In Fig. 16 we can see the expression of MAb A3G2.B4 antigen (Table 1) in differentiated 
fetal neural stem/progenitor cell lines hBrSc003 (A,B) and hBrSc005 (B). Note a clear 
heterogeneous staining of cell nuclei. In D, E,F and G the staining of glioblastoma 
spheroid cell line differentiated for 7 days, normal epithelial amniotic cells, adult skin 
fibroblasts and glioblastoma OjFe secondary cell culture are shown, respectively. Note the 
heterogeneous nuclear and nucleolar staining and a weak cytoplasma staining. However, 
in Bowes melanoma cell line both the nuclear and strong granular cytoplasmic staining 
was observed (H). 
 
 
Fig. 16. Presence of  MAb A3G2.B4 antigen in different cells. In all cases the cells were fixed 
with 4% PFA, permeabilized with Tritone X-100 and specifc staining of MAb A3G2.B4 
revealed by red staining –Alexa 594. (A,B) Human fetal hBrSc003 neurosphere cells 
differentiated for 11 days. Double immunofluorescent staining. ǃ-III-tubulin is revealed by 
green staining – Alexa 488, obj. 40x. (C) Human fetal hBrSc005 neurosphere cells 
differentiated for 7 days, obj. 40x. (D) Human glioblastoma TiVi spheroid cell line 
differentiated for 7 days. Double immunofluorescent staining. ǃ-III-tubulin is revealed by 
green staining – Alexa 488obj. 100x. (E-H) Human normal amniotic epithelial cell line KM on 
the 2nd days of cultivation, human adult skin fibroblast cell line SA-54 on the 3rd day of 
cultivation, human glioblastoma OjFe secondary cell culture on the 3rd day of cultivation , 
and Bowes melanoma cell line on the 2nd day of cultivation, respectively, obj. 100x. DAPI is 
used for nuclei staining (blue). 
In Fig. 17 and 18 the results of Western blot and molecular identification of the target 
antigen of MAb A3G2.B4 are shown. 
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Fig. 17. Western blot with MAb A3G2.B4. Target antigen Lupus La antigen was first 
immunoprecipitated with MAb A3G4.B4 in 1% NP-40 PBS solution from the concentrated 
lysate of Bowes melanoma cells. Precipitate was heated at 60°C 15 min, added urea up to 
end concentration of 2M and proteins separated in SDS-PAGE gradient (8-24%) gel. 1 – 
negative control with HRP-conjugated goat anti-mouse IgG secondary antibody; 2 – reaction 
with MAb A3G2.B4 and secondary antibody. 
  1 MAENGDNEKM AALEAKICHQ IEYYFGDFNL PRDKFLKEQI KLDEGWVPLE 
 51 IMIKFNRLNR LTTDFNVIVE ALSKSKAELM EISEDKTKIR RSPSKPLPEV 
101 TDEYKNDVKN RSVYIKGFPT DATLDDIKEW LEDKGQVLNI QMRRTLHKAF 
151 KGSIFVVFDS IESAKKFVET PGQKYKETDL LILFKDDYFA KKNEERKQNK 
201 VEAKLRAKQE QEAKQKLEED AEMKSLEEKI GCLLKFSGDL DDQTCREDLH 
251 ILFSNHGEIK WIDFVRGAKE GIILFKEKAK EALGKAKDAN NGNLQLRNKE 
301 VTWEVLEGEV EKEALKKIIE DQQESLNKWK SKGRRFKGKG KGNKAAQPGS 
351 GKGKVQFQGK KTKFASDDEH DEHDENGATG PVKRAREETD KEEPASKQQK 
401 TENGAGDQ                                             Q 
Fig. 18. Amino acid sequences of Lupus La protein. With red colour  are marked amino 
acids sequences identified by mass-spectroscopy (band 259 in Fig. 17). 
Conclusion 
On the basis of data presented above we conclude that the target antigen of MAb A3G2.B4 is 
protein Lupus La protein. According to UniProtKB/Swiss-Prot database Lupus La protein 
binds to the 3' poly(U) terminii of nascent RNA polymerase III transcripts, protecting them 
from exonuclease digestion and facilitating their folding and maturation 
(http://www.uniprot.org/uniprot/P05455). 
5. Discussion and conclusions 
The main aim of present study is the development of new monoclonal antibodies against 
neuronal tissue cells to investigate the differentiation and malignization of human nerve 
cells. The antibody producing hybridomas were obtained by immunizing mice with the 
native fragments of human glioblastoma and foetal neural stem/progenitor cells to obtain 
MAbs against all kinds of antigenic determinants, that are expressed in the living cells,  
including those determinants, that are expressed on the cell surface. From plenty of MAb-
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producing clones only those that revealed heterogeneity of reaction with stem/progenitor 
cells and glioblastoma spheroid cultures were further characterize and the target antigens 
identified. In this way there is possible to obtain panels of MAbs, that characterizes the 
given cell types, including tumour cells. The spectrum of the monoclonal antibodies 
obtained using our method is quite large, including antibodies against proteins as well as 
against their different modifications. Previously, using described approach we have 
developed MAb F10H2.B3 specific to Ku80 (ATP-dependent DNA helicase 2 subunit 2). We 
suggest this antibody could be used in certain conditions as a proliferation marker for cells 
of different origin (Mikelsaar et al., 2009). In this chapter we present the data about 
development the five new monoclonal antibodies against neural antigens 
Annexin A1 has been reported to take part in different functions as both inhibition of 
phospholipase A2, acute inflammation, pituitary hormone regulation, fever, neutrophil 
migration, cell proliferation, and stimulation of cell proliferation, differentiation, apoptosis, 
membrane repair, macrophage phagocytosis and neuroprotection (Solito et al., 2008). Less 
information is about annexin A1 expression in the developing brain. It seems to have limited 
neuronal distribution, but is strongly expressed in glia and ependymocytes (Fava et al., 
1989). The studies have shown that annexin A1 (LC-1) positive cells carry other microglial 
markers and are quite distinct from astrocytes identified by S100B immunoreactivity 
(McKanna, 1993). It has been also proposed that LC1 can be a comprehensive and reliable 
marker for microglia (McKanna & Zhang, 1997). Annexins are generally cytosolic proteins, 
soluble or reversibly associated with components of the cytoskeleton or proteins that 
mediate interactions between the cell and the extracellular matrix (matricellular proteins) 
(Moss & Morgan, 2004). In certain cases, annexins may be expressed at the cell surface, 
despite the absence of any secretory signal peptide (Solito et al., 1994). In differentiated fetal 
neural stem/progenitor (Fig. 4, A,B,C,D) and glioblastoma spheroid cells (Fig.4, E) MAb 
E14G2 antigen (annexin A1) is expressed mainly in glial cells but not in ǃ-III-tubulin 
positive neuronal cells.This observation is in accordance with data on the developing brain 
obtained by R.A.Fava and coworkers (Fava et al.,1989). Similar picture of expressing of 
annexin A1 only in limited cell types we have seen also in rat granule primary culture (Fig. 
4, H). We propose that the cell expressing annexin A1 might be a Purkinje cell, which have 
been shown to be annexin A1 positive in adult rat cerebellum (Solito et al., 2008). In rat 
granule primary culture we have also seen a small amount of GFAP+/annexin A1+ double 
positive glial cells (data not shown here). The majority of glial cells were only GFAP 
positive. The expression of annexin A1 was strong and homogenous in glioblastoma OjAr 
secondary culture and in Bowes melanoma cell lines (Fig. 4, F and G respectively). We 
propose that MAb E14G2 may be a perspective marker for some distinct neural cell types..  
Calnexin is a calcium-binding protein that interacts with newly synthesized glycoproteins in 
the endoplasmic reticulum (Ellgaard & Helenius, 2003; Ou et al, 1995). Like calreticulin, 
calnexin is predominantly located in the ER but it has also been identified at the cell surface 
of a number of cells. Okazaki Y. and co-workers (Okazaki et al., 2000) reported that a small 
fraction of calnexin is normally expressed on the surface of various cells. The results of these 
authors suggest that there is continuous exocytosis and endocytosis of calnexin, and the 
amount of calnexin on the plasma membrane results from the balance of the rates of these 
two events. The findings suggest that the surface expression of calnexin depends on the 
association with glycoproteins and that calnexin may play a certain role as a chaperone on 
the plasma membrane as well (Okazaki et al., 2000). Our observations are in good 
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accordance with previous data. We observed the expression of of MAb E15F10.B9 detected 
calnexin on the surface of unfixed human adult skin fibroblasts and on fixed, but not 
permeabilized cells of glioblastoma TiViMNBFCS10 and Bowes melanoma cell line, 
respectively (Fig. 7, E-G). In Fig. 7 we can see a different expression of MAb E15F10.B9 
detected calnexin in differentiated fetal neural stem/progenitor (A) and glioblastoma 
spheroid cells (C) in which ǃ-III-tubulin-positive cells are negative or very weakly calnexin-
positive. In the human fetal hBrSc003 neurosphere culture differentiated for 11 days we see 
at least three populations of cells, namely the calnexin+/ǃ-III-tubulin-cells, calnexin-/ǃ-III-
tubulin+ cells and also cells which are negative for both antigens. It shows that MAb 
E15F10.B9 may be used for detection of some distinct population of neural cells (see also a 
strongly calnexin+ cell among other totally calnexin- cells in TiViMNBFCS10 glioblastoma 
cell culture, Fig.7, F). Interestingly, in the unfixed human sperms we see two separate points 
between the head and neck of the sperm (H). This phenomenon needs further investigation.  
14-3-3 proteins. There are seven genes that encode 14-3-3s in most mammals (Takashi, 2003). 
14-3-3 proteins are abundantly expressed in the brain and have been detected in the 
cerebrospinal fluid of patients with different neurological disorders. By their interaction 
with more than 100 bindingpartners, 14-3-3 proteins modulate the action of proteins that are 
involved in cell cycle and transcriptional control, signal transduction, intracellular 
trafficking and regulation of ion channels. The study of some of these interactions is sheding 
light on the role of 14-3-3 proteins in processes such as apoptosis and neurodegeneration 
(Berg et al., 2003). The immunohistological and subcellular location of the 14-3-3 proteins 
was studied using different isoform-specific antisera (Martin et al., 1994). The 
immunohistochemical examination using the specific antibody showed significant staining 
of the cytoplasm, including neuronal axons and dendrites. This result was confirmed by the 
ultracentrifugal cellular fractionation method, indicating that 14-3-3 is mainly localized in 
the neuronal cytoplasm and a portion of 14-3-3 may be bound to the plasma membrane, 
endoplasmic reticulum, and Golgi membrane. This is in good accordance with our in vitro 
study on different cell lines. In Fig. 10 we see the expression of the protein 14-3-3 in the fetal 
neural stem/progenitor cell lines hBrSc006 (A) and hBrSc009 (B). The strong staining was 
seen in the cytoplasm in Golgi region, but also in cell projections and nuclei in many cells. In 
the rat granulare cell culture there are two different 14-3-3 stained cell populations, detected 
by MAb W4A8.F4: negatively stained cells and cells with positively stained cytoplasm and 
nuclei (Fig.10, H). It shows that the MAb W4A8.F4 may work in certain conditions as a 
marker for some types of neural cells. In the fetal skin fibroblasts, glioblastoma, Bowes 
melanoma and COS-1 cell lines the cytoplasm, especially Golgi region was strongly stained 
(Fig.10, C,E,F and G respectively). 
Interestingly, in the unfixed human sperms the entire tail, except the neck, was strongly and 
homogeneously stained (Fig.10, D). This is a very interesting fact and needs further 
investigation. 
Vimentins are class-III intermediate filaments found in various non-epithelial cells, 
especially mesenchymal cells. During the development of the nervous system, vimentin is 
transiently expressed in virtually all the precursors cells of both neuronal and glial lineages. 
In the astroglial cell lineage, vimentin is the only IF protein expressed in radial glia and 
immature astrocytes in the embryonic nervous system (Alonso, 2001; Colluci-Guyon et al., 
1999; Schnitzer et al., 1981). The expression of glial fibrillary acidic protein (GFAP), vimentin 
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and fibronectin (Fn) was studied in cells cultured from human glioma and fetal brain by 
indirect immunofluorescence (IIF) microscopy and multiple labelling experiments (Paetau 
1988). The results of the study demonstrate a general coexpression of GFAP and vimentin in 
cultured astroglial cells, in addition to cells expressing only vimentin. This is in good 
accordance with our data. In Fig. 13 we see the filamentous staining of the vimentin with 
MAb GB26 10G3 in human adult skin fibroblasts (A) and in glioblastoma cell line 
TiViMNBFCS10 (B). In glioblastoma cell lines the staining pattern was very heterogeneous, 
some cells did not show any signs of staining. Double staining for ǃ-III-tubulin and 
vimentin (Fig. 13,C) showed an independent staining pattern, some cells were double 
stained (vimentin+/ǃ-III-tubulin+), some cells showed only ǃ-III-tubulin staining (vimentin-
/ǃ-III-tubulin+) and the majority of cells were only vimentin positive. The double staining of 
vimentin and glial fibrillar acid protein (GFAP) is shown in Fig. 13, D. Note that all the cells 
are vimentin+/GFAP+, but show an independent staining pattern. We propose that our MAb 
GB26 10G3 may be a good additional tool for detecting and characterization of expression of 
vimentin in different types of neural cells, including glioblastomas. 
Lupus La protein (known also as Sjogren syndrome antigen B and autoantigen La) is 
ubiquitous in eukaryotic cells and associates with the 3’ termini of many newly synthesized 
small RNAs. The La protein protects the 3’ ends of these RNAs from exonucleases (Wolin & 
Cedervall, 2002). The immunohistochemical location of La antigen was shown to be the 
nucleus but an intense staining of the nucleolus was seen in human cerebral cortical neurons 
as well as a subset of neurons of rat brain (Graus et al., 1985). Further it was shown that La 
ribonucleoproteins (RNP) exist in distinct states that differ in subcellular localization (Intine 
et al., 2003). This is in good accordance with our results of the immunocytochemical study. 
In Fig. 16 we see the staining of La protein with MAb A3G2.B4 in nuclei of all cell lines 
studied. However, the staining of nuclei was very heterogeneous in differentiated fetal 
neural stem cells (A-C), clearly showing the existence of two cell population for 
MabA3G2.B4 detected La protein – La protein+ and La protein- cells. This may be a sign of 
real existence of two different cell populations and needs further investigation. A clear 
nucleolar staining was also seen in many cells, especially in normal amniocytes and 
glioblastoma cells (E-G). In the Bowes melanoma cell line both the nuclear and strong 
granular cytoplasmic staining was observed (H).  
Further perspectives. The characterization of the target antigenes and epitopes of all other 
monoclonal antibodies obtained during our main project is in progress.  
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